A comprehensive view of Amneal Pharmaceuticals LLC. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amneal launches injectable Alymsys bevacizumab-maly biosimilar in US to treat various types of cancer in adults; the drug, developed with Spanish biopharma firm mAbxience, references Genetech’s Avastin and is first Amneal generic drug in US

Amneal recalls 13 lots of Lorazepam oral concentrate, USP 2mg/mL in individual cartons due to a defect on the dropper markings; product has code NDC 65162-687-84 and contains 30mL amber glass bottle

Sandoz, Amneal, Rhodes join Teva in nationwide generic Adderall shortage as demand spikes; the firms make over half of all the generic extended-release version of the drug in US, where federal government limits amount each company can make

Amneal receives FDA ANDA approval for four generic products including Vasopressin injection, oral Famotidine, Atropine sulfate 1% ophthalmic solution, Clindamycin phosphate topical gel USP 1% 75 mL; Amneal targets 20-30 new generic launches annually

Amgen and Kashiv Biosciences get US approval for Fylnetra, a biosimilar to Amgen’s injectable Neulasta pegfilgrastim to treat neutropenia resulting from chemotherapy; in 12 months ending March 2022, Neulasta biosimilars had US sales of US$1B

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count